D.E. Shaw & Co
ABCL icon

D.E. Shaw & Co’s AbCellera Biologics ABCL Stock Holding History

D.E. Shaw & Co’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-224,600
Closed -$3.21M – 5477
2021
Q4 		$3.21M Hold
224,600
– – ﹤0.01% 2875
2021
Q3 		$4.5M Buy
+224,600
New +$3.97M ﹤0.01% 2203

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co's ABCL Position: Q1 2026 in Review

D.E. Shaw & Co sold out of AbCellera Biologics (ABCL) in Q1 2026, closing a stake of 77,776 shares — an estimated $266K sold.

D.E. Shaw & Co first reported a position in ABCL in Q3 2021 and held it in 16 quarters. The position peaked at $27.4M in Q3 2022. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • D.E. Shaw & Co reported no remaining AbCellera Biologics position as of Q1 2026 after selling out during the quarter.
  • D.E. Shaw & Co sold 77,776 AbCellera Biologics shares in Q1 2026, an estimated $266K.
  • D.E. Shaw & Co first reported a position in AbCellera Biologics in Q3 2021 and held it in 16 quarters.
  • D.E. Shaw & Co's AbCellera Biologics position peaked at $27.4M in Q3 2022.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.